Oral Treatment in Phase 2 Trial, NYX-458, Seen to Aid Cognition in Primate Model Study

Oral Treatment in Phase 2 Trial, NYX-458, Seen to Aid Cognition in Primate Model Study
Aptinyx‘s investigational oral compound NYX-458 was able to ease cognitive difficulties in a non-human primate model of Parkinson’s disease, including attention, working memory and executive thinking, a study reports. Its findings also suggest that NYX-458 — now in a Phase 2 clinical trial (NCT04148391) enrolling patients across the U.S. — does not interfere with levodopa treatment. The study, “NYX‐458 improves cognitive ... read more
Source: Parkinson’s News TodayPublished on 2020-02-05By Marisa Wexler